QCOR News 90.20 05/28/2014 05:21:59 Questcor Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Questcor Pharmaceuticals (QCOR) 90.20 $QCOR

Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...

Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 38.4% (QCOR)
Comtex SmarTrend(R) - Thu May 22, 9:36AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 38.41% as of today's recent price of $93.30.

Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com
PR Newswire - Thu May 22, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.

Downgrade Alert for Questcor Pharmaceuticals (QCOR)
Comtex SmarTrend(R) - Tue May 20, 6:56AM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $92.08 on volume of 2.0 million shares, below average daily volume of 3.5 million. Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company's primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.

Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology
PR Newswire - Tue May 20, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2665-100free.

SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.80% Gain
Comtex SmarTrend(R) - Fri May 16, 4:18PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.28 to a high of $90.93. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $88.94 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Shares of QCOR Up 30.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:11AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 30.01% as of today's recent price of $87.64.

Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?

Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
PR Newswire - Wed May 14, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen®, this transaction significantly expands Questcor's portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.

Post Earnings Update: Questcor Pharmaceuticals Has Climbed 10.5% Higher in Past 2 Weeks (QCOR)
Comtex SmarTrend(R) - Mon May 12, 11:42AM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.61 on sales of $240.8 million. Questcor Pharmaceuticals actually reported earnings of $1.51 per share on sales of $227.1 million, missing EPS estimates by $0.10 and missing revenue estimates by $13.6 million. Since the company's report, shares of Questcor Pharmaceuticals have risen from $79.05 to $87.34, representing a gain of 10.5% in the past 14 days.

Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
Business Wire - Mon May 12, 6:01AM CDT
Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR" , in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014.

Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.

Scanning Equities that Reached New highs -- Research on Energy Transfer Equity, Questcor Pharma, Health Net, and Molson Coors Brewing
PR Newswire - Thu May 08, 12:30PM CDT
The markets on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished the day at 16,518.54, up 0.72%, and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the session 0.56% higher at 1,878.21. The gains were broad based as eight out of ten sectors ended the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Energy Transfer Equity L.P. (NYSE: ETE), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Health Net Inc. (NYSE: HNT) and Molson Coors Brewing Company (NASDAQ: TAP). Free technical research on ETE, QCOR, HNT and TAP can be downloaded upon signing up at:

Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....

Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance
Business Wire - Thu May 08, 5:01AM CDT
--Increases guidance on full-year revenue and full-year adjusted diluted earnings per share reflecting strength of base business and acquisition of Cadence

After Yesterday's Rally of 2.53% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed May 07, 5:17PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $83.51 to a high of $86.51. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $85.00 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 50

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Pan Global Thrives with Key Developments in Spanish Projects

Updated Category News Views 224

Pan Global Resources Making Waves in Spain Pan Global Resources Inc. (TSXV: PGZ | OTCQX: PGZFF | FRA: 2EU) is currently marking a pivotal phase in its operations, focusing on two notable projects located in Spain: Escacena and Cármenes. The company has reported impressive results from its exploration programs throughout the year, indicating significant growth potential...

Continue Reading
Hazelview Cares Foundation: Empowering Communities for a Brighter Future

Updated Category News Views 183

Introducing the Hazelview Cares Foundation Hazelview Investments is excited to announce the establishment of the Hazelview Cares Foundation, which aims to enhance and uplift the communities where it operates. This not-for-profit organization focuses on creating opportunities for individuals and families to thrive, ensuring that everyone has the potential to achieve their...

Continue Reading
Merritt Properties Expands Offerings with New Tenants

Updated Category News Views 123

Merritt Properties Approaches Full Occupancy Merritt Properties is excited to announce that its North Chapel Business Center is close to achieving full occupancy, with only 3,600 square feet of space remaining. A major milestone has been reached with the Chapel Hill Police Department committing to a lease of 58,000 square feet for a new headquarters, which is set to open...

Continue Reading
Understanding Short Interest Trends for TJX Companies

Updated Category News Views 357

Analyzing Short Interest Trends for TJX Companies TJX Companies (NYSE: TJX) is seeing a notable decline in its short percent of float, which has recently fallen by 9.3%. The latest figures indicate that there are 13.22 million shares sold short, accounting for 1.17% of the total regular shares available for trading. With the current trading volume, it is estimated that...

Continue Reading
Jet.AI Reaches New Depths as Market Pressures Mount

Updated Category News Views 48

Jet.AI Stock Hits 52-Week Low In a challenging market landscape, Jet.AI's stock has recently hit a 52-week low of just $0.08. This dramatic decrease in stock value signals a broader trend of caution among investors, as Jet.AI navigates through a multitude of internal and external challenges. Over the last year, the stock has seen a staggering decline, reflecting a 97.19%...

Continue Reading